Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
 
Sign in
Join now
featured
Published in COVID-19 and
2 other channels

Journal Scan / Research · October 03, 2021

Safety and Antibody Response After mRNA Vaccine in Allogeneic HSCT Recipients

JAMA Network Open

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Ella Ariza-Heredia MD

Roy Chemaly MD, MPH

JAMA Network Open
Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
JAMA Netw Open 2021 Sep 01;4(9)e2126344, A Le Bourgeois, M Coste-Burel, T Guillaume, P Peterlin, A Garnier, MC Béné, P Chevallier

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated